H. Lee Moffitt Cancer Center & Research Institute

Physician, Faculty, and Staff

Susan E. Minton, DO

Susan E. Minton, DO

Faculty Rank:

Associate Member

Titles:

Department/Program Affiliations:

  • Experimental Therapeutics  
  • Breast  

Primary Address:

H. Lee Moffitt Cancer Center &
Research Institute
12902 Magnolia Drive
Tampa, FL 33612

Consultation/Referral Phone:

(813) 745-8410

USF Affiliations/College Department:

  • Medicine / Oncologic Sciences
  • Medicine / Internal Medicine

University Academic Rank:

Associate Professor

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Susan E. Minton, DO

Education & Training:

  • D.O., University of Medicine & Dentistry of New Jersey, 1989
  • Internship, Sun Coast Hospital, 1990
  • Residency, University of Florida Health Science Center of Jacksonville, 1993 - Internal Medicine
  • Fellowship, University of South Florida, 1996 - Hematology & Oncology
  • B.S., Cook College, Rutgers University, New Brunswick, New Jersey, 1984 - Food Science

General Board Certification / SubSpecialty:

  • Internal Medicine / Medical Oncology
  • Internal Medicine / Hematology

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Susan E. Minton, DO

Research Interests:

Translational research investigating novel molecular markers for breast cancer. Clinical translational neoadjuvant treatment trials for high-risk breast cancer.


Clinical Interests:

Treatment for neoadjuvant and metastatic breast cancer.

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Susan E. Minton, DO

Publications:

  1. Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D. Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC. Clin Cancer Res. 2009 Apr;15(7):2488-2496. Pubmedid: 19318486.   Pubmed ID: 19318486

  2. Munster P, Britten C, Mita M, Gelmon K, Minton S, Moulder S, Slamon D, Guo F, Letrent S, Denis L, Tolcher A. First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors. Clin Cancer Res. 2007 Feb;13(4):1238-1245. Pubmedid: 173.   Pubmed ID: 173

  3. Munster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol. 2007 May;25(15):1979-1985. Pubmedid: 17513804.   Pubmed ID: 17513804

  4. Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L, Tolcher AW. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin Cancer Res. 2007 Feb;13(4):1238-1245. Pubmedid: 17317835.   Pubmed ID: 17317835

  5. Cox C, Cox J, White L, Stowell N, Clark J, Allred N, Meyers M, Dupont E, Furman B, Minton S. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer. Ann Surg Oncol. 2006 Apr;13(4):483-490. Pubmedid: 16523361.   Pubmed ID: 16523361

  6. Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, Eweis I, Wloch M, Livingston S, Seijo E, Cantor A, Lee JH, Beam CA, Sullivan D, Jove R, Muro-Cacho CA. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res. 2006 Jan;12(1):20-28. Pubmedid: 16397019.   Pubmed ID: 16397019

  7. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, Yoder S, Enkemann S, Eschrich S, Lee J, Beam C, ChengJ, Minton S, Muro-Cacho C, Jove R. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 2006 Jan;12(1):11-19. Pubmedid: 16397018.   Pubmed ID: 16397018

  8. Kumar N, Allen K, Riccardi D, Bercu B, Cantor A, Minton S, Balducci L, Jacobsen P. Fatigue, weight gain, lethargy and amenorrhea in breast cancer patients on chemotherapy: is subclinical hypothyroidism the culprit. Breast Cancer Res Treat. 2004;83(2):149-159. Pubmedid: 14997046.   Pubmed ID: 14997046

  9. Minton S, Munster P. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2002;9(6):466-471. Pubmedid: 12514564.   Pubmed ID: 12514564

  10. Minton S, Munster P. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2002;9(6):466-472. Pubmedid: 12514564.   Pubmed ID: 12514564

  11. Weitzner M, Moncello J, Jacobsen P, Minton S. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage. 2002;23(4):337-345. Pubmedid: 11997203.   Pubmed ID: 11997203

  12. Garcia R, Bowman T, Niu G, Minton S, Muro-Cacho C, Cox C, Kraker A, Levitzki A, Parsons S, Jove R, Falcone R, Fairclough R, Yu H, Laudano A, Gazit A. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 2001;20(20):2499-2513. Pubmedid: 11420660.   Pubmed ID: 11420660

  13. Minton S. Chemoprevention of breast cancer in the older patient. Hematol Oncol Clin North Am. 2000;14(1):113-129. Pubmedid: 10680075.   Pubmed ID: 10680075

  14. Minton S. Breast cancer treatment: prospects for the future. Cancer Control. 1999;6:215-217. Pubmedid: 10758551.   Pubmed ID: 10758551

  15. Minton S. New hormonal therapies for breast cancer. Cancer Control. 1999;6(3):247-255. Pubmedid: 10758554.   Pubmed ID: 10758554

  16. Sutphen R, Diamond T, Minton S, Peacocke M, Root A. Severe Lhermitte-Duclos disease with unique germline mutation of PTEN. Am J Med Genet. 1999;82(4):290-293. Pubmedid: 10051160.   Pubmed ID: 10051160

  17. Lyman G, Kuderer N, Lyman S, Debus M, Minton S, Balducci L, Horton J, Reintgen D, Cox C. Menopausal status and the impact of early recurrence on breast cancer survival. Cancer Control. 1997;4(4):335-341. Pubmedid: 10763039.   Pubmed ID: 10763039

  18. Minton S, Shaw G. Chemoprevention of cancer in the elderly. In: Balducci L, Lyman G, Ershler W, et al, eds. Comprehensive Geriatric Oncology. Harwood Academic Publishers; 1998;307-324.  

Susan E. Minton, DO

Below is a list of active grants where the faculty member is the Principal Investigator. Grants are sorted by sponsor and then sorted by start date, with the more recent grant shown first.

Phase I Investigation of MK-5108 and MK-5108 with Docetaxel in Pts w Adv Solid Tumors
Sponsor: Merck & Co., Inc.
Project Dates: May 1, 2008 to April 30, 2011
Annual Direct Cost: $7,430
Annual Total Cost: $9,659
Project Total: $152,290

Study of Tamoxifen & Raloxifine (STAR) for the Prevention of Breast CA
Sponsor: NSABP / NCI
Project Dates: August 4, 1999 to August 3, 2011
Annual Direct Cost: $7,800
Annual Total Cost: $7,800
Project Total: $39,976

Physician/Faculty  Contact Form

© Copyright 1996 - 2010 H. Lee Moffitt Cancer Center & Research Institute